A strategic market access consultant won’t create a strategy for you but can help a great deal in optimal decision making and saving money down the road. Here are 5 reasons why you need one.
Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.
The Challenge Our client, a mid-size biopharmaceutical company partnered with Inbeeo to develop a payer value story that can consider different clinical outcomes and be
The Challenge Inbeeo’s client was a small clinical stage pharmaceutical company exploring the clinical potential of an asset with promising efficacy across several different pathologies,
The Challenge Inbeeo’s client, a large pharmaceutical company, launched a product in an ultra-orphan indication. Following the publication of promising clinical results, they were looking
The Challenge Inbeeo’s client, a large global pharmaceutical company, is developing new cell therapies for Parkinson’s Disease and Chronic Heart Failure, . They engaged Inbeeo
The Challenge Inbeeo’s client is currently developing a product in a highly competitive CNS indication (PD). After an online survey provided early perspectives into the
The Challenge Inbeeo’s client, a global leader in chronic disease, is embarking on an exciting journey to develop cell therapies in four indications. Whilst an
